Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia

Vey, N; Prebet, T; Thalamas, C; Charbonnier, A; Rey, J; Kloos, I; Liu, E; Luan, Y; Vezan, R; Graef, T; Recher, C

Vey, N (reprint author), Dept Hematol, 232 Blvd Sainte Marguerite,BP 156-13273, Marseille 9, France.

LEUKEMIA & LYMPHOMA, 2017; 58 (8): 1880

Abstract

Histone deacetylase (HDAC) inhibitor abexinostat is under investigation for the treatment of various cancers. Epigenetic changes including aberrant HD......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索